Researchers developed and validated a diagnostic prediction model to distinguish between juvenile idiopathic arthritis and chronic musculoskeletal pain syndrome.
Study authors assessed the prevalence of sarcopenia in patients with pain and the association between pain and sarcopenia.
Laboratory analyses revealed certain Artri and Ortiga products contain undeclared drug ingredients.
Osteopathic manipulative treatment (OMT) may be effective for musculoskeletal disorders.
A EULAR taskforce developed recommendations regarding lifestyle behaviors and work participation to prevent progression of rheumatic and musculoskeletal diseases among patients.
Osteoporosis treatment and prevention doses including recommended calcium and vitamin D supplemental doses.
Study authors described antibody responses among patients with rheumatic and musculoskeletal diseases receiving immunosuppressant therapy 6 months after completing the COVID-19 vaccine series.
A EULAR task force recently developed recommendations for the management of cardiovascular risk in patients with rheumatic and musculoskeletal diseases, including gout, lupus, and systemic sclerosis.
The American College of Rheumatology updated dosing and timing considerations for COVID-19 vaccines among patients with rheumatic and musculoskeletal diseases.
Using data from the COVAX physician-reported registry, researchers studied the safety of SARS-CoV-2 vaccines in patients with inflammatory/autoimmune rheumatic and musculoskeletal diseases.
